GlassScriptPhysician profile
Mohamed Shafiu
NPI 1174685648
$8,506.20
in general payments reported to CMS, 2019-2025
31 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $490 · 2021: $649 · 2022: $1,262 · 2023: $1,477 · 2024: $1,867 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,046 · Education: $49.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,045.61 |
| Education | $49.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,874.93 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $975.77 | 2020-2025 | Velphoro, Velphoro |
| Amgen INC. | $586.98 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Opko Pharmaceuticals, LLC | $578.24 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $494.43 | 2020-2024 | Auryxia, Vafseo |
| Novartis Pharmaceuticals Corporation | $455.38 | 2019-2025 | |
| Daiichi Sankyo INC. | $409.84 | 2019-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $329.26 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $309.51 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $308.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $301.19 | 2022-2024 | Benlysta, Jesduvroq |
| Merck Sharp & Dohme LLC | $282.63 | 2021-2024 | Verquvo |
| Horizon Therapeutics Plc | $274.19 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.50 | 2019-2025 | Jardiance |
| Vifor Pharma, INC. | $196.37 | 2019-2024 | Veltassa, Korsuva |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $163.48 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $133.10 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $81.39 | 2024-2025 | Wegovy |
| Ani Pharmaceuticals, INC. | $78.83 | 2023 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $74.43 | 2025 | |
| Shield Therapeutics INC | $61.20 | 2024-2025 | |
| Lilly USA, LLC | $50.76 | 2024-2025 | Jardiance |
| Outset Medical INC | $43.34 | 2022 | |
| Arbor Pharmaceuticals, INC. | $43.00 | 2019-2020 | |
| Ardelyx, INC. | $36.40 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.40 | 2020 | |
| Cormedix INC. | $24.73 | 2024 | Defencath |
| Abbott Laboratories | $20.17 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.21 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.15 | 2023 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $13.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Shafiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.